Deucravacitinib

Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target. It is grouped under the following drug class(es): Immunosuppressants, JAK inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-inflammatories, anti-psoriatic agents and dermatologicals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Sotyktu. Its PubChem CID is 134821691.